首页> 外文期刊>Medical hypotheses >Palmitoylethanolamide: From endogenous cannabimimetic substance to innovative medicine for the treatment of cannabis dependence
【24h】

Palmitoylethanolamide: From endogenous cannabimimetic substance to innovative medicine for the treatment of cannabis dependence

机译:棕榈酰乙醇酰胺:从内源性模拟大麻物质到创新药物,用于治疗大麻依赖性

获取原文
获取原文并翻译 | 示例
           

摘要

Palmitoylethanolamide (PEA) is a fatty acid amide showing some pharmacodynamic similarities with δ9-tetrahydrocannabinol, the principal psychoactive compound present in the cannabis plant. Like δ9-tetrahydrocannabinol, PEA can produce a direct or indirect activation of cannabinoid receptors. Furthermore, it acts as an agonist at TRPV1 receptor. The hypothesis is that PEA has anti-craving effects in cannabis dependent patients, is efficacious in the treatment of withdrawal symptoms, produces a reduction of cannabis consumption and is effective in the prevention of cannabis induced neurotoxicity and neuro-psychiatric disorders.
机译:棕榈酰乙醇酰胺(PEA)是一种脂肪酸酰胺,与大麻植物中存在的主要精神活性化合物δ9-四氢大麻酚具有某些药效学相似性。像δ9-四氢大麻酚一样,PEA可以直接或间接激活大麻素受体。此外,它还充当TRPV1受体的激动剂。假设是,PEA在依赖大麻的患者中具有抗渴望的作用,可有效治疗戒断症状,​​减少大麻消费,并有效预防大麻诱发的神经毒性和神经精神疾病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号